Factors Associated Intracranial Haemorrhage after rtPA in Acute Stroke
Keywords:
factor, acute stroke, thrombolytic, intracranial hemorrhageAbstract
ABSTRACT
Mortality rate of Acute ischemic stroke is 62.2 percent. Recombinant tissue plasminogen activator (rtPA) is recommended to treat acute ischemic stroke but intracranial bleeding is its main adverse effect that lead to increase morbidity and mortality.
Objectives: The aim was to determine factors that associated intracranial haemorrhage after treatment with rtPA.
Methods: This retrospective study collected stroke fast tract data from 1 January 2013 to 31 December 2019 in Ratchaburi Hospital. Demographic data, clinical data, and laboratory result were collected from the electronic and admission data. All data was analyzed to find factors that associated intracranial hemorrhage.
Results: We collected 256 patients from electronic and admission data. Six patients were excluded by incomplete data. Intracranial hemorrhage occurred in 37 patients. It was calculated to 14.8 percent. Factor that associated intracranial haemorrhage after treatment with rtPA was NIHSS. NIHSS score in intracranial hemorrhage group was higher than the other group 13(10.5-19.0) vs 10(7-15) p=.002. In subgroup analysis of intracranial hemorrhage, the death group had diastolic blood pressure and blood sugar higher than the survival group 104(18.66) vs 82.79(14.28) p=.001 and 165(119.00-257.50) vs 110.50(99.25-143.00) p=.015 respectively.
Conclusions: NIHSS was the factor that associated intracranial haemorrhage after treatment with rtPA
References
1. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019; 139(10): e56-e528. doi: 10.1161/CIR.0000000000000659.
2. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018; 49(3): e46-e110. doi: 10.1161/STR.0000000000000158.
3. Atlantis T, Study PA, Investigators G. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363(9411) :768–74. doi: 10.1016/S0140-6736(04)15692-4.
4. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-analysis. Lancet. 2012; 379(9834): 2364–72. doi: 10.1016/S0140-6736(12)60738-7.
5. Yaghi S, Willey JZ, Cucchiara B, et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017; 48(12): e343–61. doi: 10.1161/STR.0000000000000152.
6. Strbian D, Sairanen T, Meretoja A, et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011; 77(4): 341–8. doi: 10.1212/WNL.0b013e3182267b8c.
7. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317-29.
8. Adams HP, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999; 53(1): 126–31. doi: 10.1212/wnl.53.1.126.
9. Cucchiara B, Tanne D, Levine SR, et al. A Risk Score to Predict Intracranial Hemorrhage After Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2008; 17(6): 331–3. doi: 10.1016/j.jstrokecerebrovasdis.2008.03.012.
10. Lou M, Safdar A, Mehdiratta M, , et al. The HAT Score: A simple grading scale for predicting hemorrhage after thrombolysis. Neurology. 2008; 71(18): 1417–23. doi: 10.1212/01.wnl.0000330297.58334.dd.
11. Strbian D, Engelter S, Michel P, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: The SEDAN score. Ann Neurol. 2012; 71(5): 634–41. doi: 10.1002/ana.23546.
12. Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012; 43(6): 1524–31. doi: 10.1161/STROKEAHA.111.644815.
13. Menon BK, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012; 43(9): 2293–9. doi: 10.1161/STROKEAHA.112.660415.
14. Flint AC, Cullen SP, Faigeles BS, et al. Predicting long-term outcome after endovascular stroke treatment: The totaled health risks in vascular events score. Am J Neuroradiol. 2010; 31(7): 1192–6. doi: 10.3174/ajnr.A2050.
15. Saposnik G, Guzik AK, Reeves M, et al. Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100. Neurology. 2013; 80(1): 21–8. Doi: 10.1212/WNL.0b013e31827b1ace.
16. Strbian D, Meretoja A, Ahlhelm FJ, et al. Predicting outcome of IV thrombolysis - Treated ischemic stroke patients: The DRAGON score. Neurology. 2012; 78(6): 427–32. doi: 10.1212/WNL.0b013e318245d2a9.
17. Guo Y, Yang Y, Zhou M, et al. Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: A systematic review and meta-analysis. Stroke Vasc Neurol. 2018; 3(4): 203–8. Doi : 10.1136/svn-2018-000141.
18. Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011; 123(7): 750–8. doi: 10.1161/CIRCULATIONAHA.110.974675.
19. Liu M, Pan Y, Zhou L, et al. Predictors of post-thrombolysis symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke. 2017 ;12(9):e0184646. Doi: 10.1371/journal.pone.0184646.
20. Suankool S, Lokeskrawee T. Factors affecting Intracerebral Hemorrhage following Intravenous Thrombolysis in Patient with Acute Ischemic Stroke. Lampang Medical Journal. 2016; 37(2): 67–77.
21. Phankhian P. Factors Affecting the Occurence of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy. Region 4-5 Medical Journal. 2015; 34(2): 120–30.
22.Enderlein G. Daniel, Wayne W.: Biostatistics — A Foundations for Analysis in the Health Sciences. Wiley & Sons, New York—Chichester—Brisbane—Toronto—Singapore, 6th ed. 1995, 780 S., £58.—, ISBN 0–471–58852-0 (cloth). Biometrical J. 1995; 37(6).
23. Guo Y, Yang Y, Zhou M, et al. Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis. Stroke and Vascular Neurology 2018; 3: e000141.
24. Fiorelli M, Bastianello S, Kummer RV, et al. Hemorrhagic Transformation Within 36 Hours of a Cerebral Infarct. Stroke 1999; 30(11): 2280-4. Doi: 10.1161/01.str.30.11.2280.
25. Berger C, Fiorelli M, Steineret T, et al. Hemorrhagic Transformation of Ischemic Brain Tissue. Stroke. 2001; 32(6): 1330-5. DOI: 10.1161/01.str.32.6.1330.
Downloads
Published
How to Cite
Issue
Section
License
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
